RESUMEN
BACKGROUND: Patients with idiopathic membranous nephropathy (IMN) are more likely to be complicated by venous thromboembolism (VTE). The aim of the study was to investigate the potential association between anti-phospholipase A2 receptor (PLA2R) antibodies and hypercoagulability in patients with IMN. METHODS: A total of 168 patients with biopsy-proven IMN and 36 patients with biopsy-proven minimal change disease (MCD) were enrolled in this study. The clinical data, serum anti-PLA2R antibodies and coagulation-related indices of the patients were retrospectively analyzed. RESULTS: Patients with IMN were categorized into glomerular PLA2R staining-positive (GAg+) IMN group and glomerular PLA2R staining-negative (GAg-) IMN group in the study. Patients with IMN who were GAg + had lower PT, APTT and R time than patients with IMN who were GAg-, while the CI value was higher in patients with IMN who were GAg+. Patients with IMN who were GAg + were divided into the SAb+/GAg + group and the SAb-/GAg + group. Patients with IMN who were SAb+/GAg + had higher Fib and MA values than patients with IMN who were SAb-/GAg+. Correlation analysis showed that serum anti-PLA2R antibodies were positively correlated with fibrinogen, D-dimer, K time, CI value, α-angle, and MA value. Multiple linear regression analysis indicated that anti-PLA2R antibodies were independently correlated with fibrinogen and MA value. CONCLUSION: Our study provides a new perspective on the underlying mechanisms of hypercoagulability in patients with IMN. Anti-PLA2R antibodies are associated with hypercoagulability in patients with IMN and may affect coagulation in patients with IMN by affecting platelet aggregation function and fibrinogen counts.
Asunto(s)
Autoanticuerpos , Glomerulonefritis Membranosa , Receptores de Fosfolipasa A2 , Trombofilia , Humanos , Receptores de Fosfolipasa A2/inmunología , Glomerulonefritis Membranosa/sangre , Glomerulonefritis Membranosa/inmunología , Glomerulonefritis Membranosa/complicaciones , Masculino , Femenino , Estudios Retrospectivos , Persona de Mediana Edad , Adulto , Trombofilia/etiología , Trombofilia/inmunología , Trombofilia/sangre , Autoanticuerpos/sangreRESUMEN
RATIONALE: The phenomenon of hypercoagulability has not been previously documented in individuals with Morvan's syndrome, especially in those associated with contactin-associated protein-like receptor 2 (CASPR2). PATIENT CONCERNS: A previously healthy 32-year-old Chinese male was admitted to the hospital with central and peripheral neurologic symptoms. The patient was tested positive for anti-CASPR2 antibodies, and also presented with an activated coagulation state on admission, characterized by a low activated partial thromboplastin time and a high platelet count. With gradual improvement of clinical symptoms, activated partial thromboplastin time, and platelet count returned to normal. Simultaneously, anti-CASPR2 antibody titers significantly decreased and eventually became undetectable. DIAGNOSES: The patient was diagnosed as Morvan's syndrome with positive anti-CASPAR2 antibodies accompanied with hypercoagulable state. INTERVENTIONS: Plasmapheresis was administered to improve the symptoms combined with prednisolone acetate therapy. OUTCOMES: The patient experienced complete resolution of all symptoms during hospitalization and generally recovery after 2 months of discharge. LESSONS: Emphasis should be directed towards hypercoagulability in individuals diagnosed with Morvan's syndrome, particularly those presenting with positive anti-CASPR2 antibodies. Anticoagulant therapy may represent a novel therapeutic approach for individuals afflicted with Morvan's syndrome and exhibiting positivity for anti-CASPR2 antibodies.
Asunto(s)
Autoanticuerpos , Proteínas de la Membrana , Proteínas del Tejido Nervioso , Trombofilia , Humanos , Masculino , Adulto , Trombofilia/inmunología , Trombofilia/tratamiento farmacológico , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Proteínas de la Membrana/inmunología , Proteínas del Tejido Nervioso/inmunología , PlasmaféresisRESUMEN
INTRODUCTION: Diabetes is the most common of comorbidity in patients with SARS-COV-2 pneumonia. Coagulation abnormalities with D-dimer levels are increased in this disease. OBJECTIFS: We aimed to compare the levels of D-dimer in diabetic and non-diabetic patients with COVID 19. A link between D-dimer and mortality has also been established. MATERIALS: A retrospective study was carried out at the University Hospital Center of Oujda (Morocco) from November 01st to December 01st, 2020. Our study population was divided into two groups: a diabetic group and a second group without diabetes to compare clinical and biological characteristics between the two groups. In addition, the receiver operator characteristic curve was used to assess the optimal D-dimer cut-off point for predicting mortality in diabetics. RESULTS: 201 confirmed-COVID-19-patients were included in the final analysis. The median age was 64 (IQR 56-73), and 56% were male. Our study found that D-dimer levels were statistically higher in diabetic patients compared to non-diabetic patients. (1745 vs 845 respectively, P = 0001). D-dimer level > 2885 ng/mL was a significant predictor of mortality in diabetic patients with a sensitivity of 71,4% and a specificity of 70,7%. CONCLUSION: Our study found that diabetics with COVID-19 are likely to develop hypercoagulation with a poor prognosis.
Asunto(s)
COVID-19/sangre , Diabetes Mellitus/sangre , Productos de Degradación de Fibrina-Fibrinógeno/análisis , SARS-CoV-2 , Trombofilia/sangre , Anciano , Área Bajo la Curva , Biomarcadores , Proteína C-Reactiva/análisis , COVID-19/complicaciones , COVID-19/epidemiología , Comorbilidad , Complicaciones de la Diabetes/sangre , Complicaciones de la Diabetes/epidemiología , Diabetes Mellitus/epidemiología , Femenino , Mortalidad Hospitalaria , Humanos , Hipertensión/epidemiología , Inflamación/inmunología , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Estrés Oxidativo , Pronóstico , Curva ROC , Estudios Retrospectivos , Factores de Riesgo , Trombofilia/etiología , Trombofilia/inmunologíaRESUMEN
Antiphospholipid antibodies (aPLs), present in 1-5 % of healthy individuals, are associated with the risk of antiphospholipid syndrome (APS), which is the most common form of acquired thrombophilia. APLs may appear following infections or vaccinations and have been reported in patients with COronaVIrus Disease-2019 (COVID-19). However, their association with COVID-19 vaccination is unclear. Notably, a few cases of thrombocytopenia and thrombotic events resembling APS have been reported to develop in recipients of either adenoviral vector- or mRNA-based COVID-19 vaccines. The aim of this review is therefore to speculate on the plausible role of aPLs in the pathogenesis of these rare adverse events. Adenoviral vector-based vaccines can bind platelets and induce their destruction in the reticuloendothelial organs. Liposomal mRNA-based vaccines may instead favour activation of coagulation factors and confer a pro-thrombotic phenotype to endothelial cells and platelets. Furthermore, both formulations may trigger a type I interferon response associated with the generation of aPLs. In turn, aPLs may lead to aberrant activation of the immune response with participation of innate immune cells, cytokines and the complement cascade. NETosis, monocyte recruitment and cytokine release may further support endothelial dysfunction and promote platelet aggregation. These considerations suggest that aPLs may represent a risk factor for thrombotic events following COVID-19 vaccination, and deserve further investigations.
Asunto(s)
Anticuerpos Antifosfolípidos/análisis , Anticuerpos Antifosfolípidos/inmunología , Vacunas contra la COVID-19/efectos adversos , Vacunas contra la COVID-19/inmunología , Trombofilia/etiología , Síndrome Antifosfolípido/etiología , Síndrome Antifosfolípido/inmunología , Contraindicaciones de los Medicamentos , Humanos , Trombofilia/inmunologíaRESUMEN
Coronavirus disease 2019 (COVID-19) is the most devastating infectious disease in the 21st century with more than 2 million lives lost in less than a year. The activation of inflammasome in the host infected by SARS-CoV-2 is highly related to cytokine storm and hypercoagulopathy, which significantly contribute to the poor prognosis of COVID-19 patients. Even though many studies have shown the host defense mechanism induced by inflammasome against various viral infections, mechanistic interactions leading to downstream cellular responses and pathogenesis in COVID-19 remain unclear. The SARS-CoV-2 infection has been associated with numerous cardiovascular disorders including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. The inflammatory response triggered by the activation of NLRP3 inflammasome under certain cardiovascular conditions resulted in hyperinflammation or the modulation of angiotensin-converting enzyme 2 signaling pathways. Perturbations of several target cells and tissues have been described in inflammasome activation, including pneumocytes, macrophages, endothelial cells, and dendritic cells. The interplay between inflammasome activation and hypercoagulopathy in COVID-19 patients is an emerging area to be further addressed. Targeted therapeutics to suppress inflammasome activation may have a positive effect on the reduction of hyperinflammation-induced hypercoagulopathy and cardiovascular disorders occurring as COVID-19 complications.
Asunto(s)
COVID-19/complicaciones , Enfermedades Cardiovasculares/etiología , Inflamasomas/inmunología , Trombofilia/etiología , Animales , COVID-19/inmunología , COVID-19/patología , Enfermedades Cardiovasculares/inmunología , Enfermedades Cardiovasculares/patología , Humanos , Proteína con Dominio Pirina 3 de la Familia NLR/inmunología , SARS-CoV-2/inmunología , Trombofilia/inmunología , Trombofilia/patologíaRESUMEN
Certain miscarriages result from immunologic factors, but there is no clear identification of the precise causes of recurrent pregnancy loss (RPL). Miscarriages and RPL can arise from a disruption of maternal-fetal immune homeostasis. Remodeling of the maternal uterine spiral arteries is one of the key steps for normal growth and development of the fetus. An adequate oxygen supply is necessary for correct placentation, and it is accomplished by proper vascular changes. The development of fetal tissues creates a potential immunologic problem since the fetus can express paternal antigens and, in some cases, antigens of a gamete donor. The maternal immune system actively responds to fetal antigens, and dysregulation of this crosstalk could partly explain pregnancy complications such as miscarriages and RPL. RPL resulting from thrombophilia is primarily due to acquired thrombophilia, and therefore screening and treatment should be focused on antiphospholipid antibody syndrome.
Asunto(s)
Aborto Habitual/inmunología , Tolerancia Inmunológica/inmunología , Factores Inmunológicos/inmunología , Placentación/inmunología , Trombofilia/inmunología , Aborto Habitual/diagnóstico , Aborto Habitual/etiología , Femenino , Humanos , Embarazo , Trombofilia/complicaciones , Trombofilia/diagnósticoAsunto(s)
Anticuerpos Antifosfolípidos/inmunología , COVID-19/inmunología , Enfermedad Crítica , Trombofilia/inmunología , Adulto , Francia , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/inmunología , Neumonía Viral/virología , Pronóstico , Estudios Retrospectivos , SARS-CoV-2Asunto(s)
Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/diagnóstico , COVID-19/inmunología , Trombofilia/inmunología , Anticuerpos Anticardiolipina/inmunología , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/inmunología , COVID-19/sangre , Humanos , Inmunoglobulina M/inmunología , Inhibidor de Coagulación del Lupus/inmunología , SARS-CoV-2 , Trombofilia/sangre , Trombosis/sangre , Trombosis/inmunología , beta 2 Glicoproteína I/inmunologíaRESUMEN
The clinical progression of the severe acute respiratory syndrome coronavirus 2 infection, coronavirus 2019 (COVID-19), to critical illness is associated with an exaggerated immune response, leading to magnified inflammation termed the "cytokine storm." This response is thought to contribute to the pathogenicity of severe COVID-19. There is an initial weak interferon response and macrophage activation that results in delayed neutrophil recruitment leading to impeded viral clearance. This causes prolonged immune stimulation and the release of proinflammatory cytokines. Elevated inflammatory markers in COVID-19 (e.g., d-dimer, C-reactive protein, lactate dehydrogenase, ferritin, and interleukin-6) are reminiscent of the cytokine storm seen in severe hyperinflammatory macrophage disorders. The dysfunctional immune response in COVID-19 also includes lymphopenia, reduced T cells, reduced natural killer cell maturation, and unmitigated plasmablast proliferation causing aberrant IgG levels. The progression to severe disease is accompanied by endotheliopathy, immunothrombosis, and hypercoagulability. Thus, both parts of the immune system-innate and adaptive-play a significant role in the cytokine storm, multiorgan dysfunction, and coagulopathy. This review highlights the importance of understanding the immunologic mechanisms of COVID-19 as they inform the clinical presentation and advise potential therapeutic targets.
Asunto(s)
Inmunidad Adaptativa/inmunología , COVID-19/inmunología , Síndrome de Liberación de Citoquinas/inmunología , Inmunidad Innata/inmunología , Síndrome de Dificultad Respiratoria/inmunología , Formación de Anticuerpos , Antivirales/uso terapéutico , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , COVID-19/sangre , COVID-19/fisiopatología , Inactivadores del Complemento/uso terapéutico , Citocinas/antagonistas & inhibidores , Citocinas/inmunología , Endotelio Vascular/inmunología , Endotelio Vascular/fisiopatología , Humanos , Inmunidad Humoral/inmunología , Inmunoglobulina G/inmunología , Factores Inmunológicos/uso terapéutico , Memoria Inmunológica , Inmunosupresores/uso terapéutico , Interferones/inmunología , Células Asesinas Naturales/inmunología , Linfopenia/inmunología , Activación de Macrófagos/inmunología , Infiltración Neutrófila/inmunología , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica/inmunología , Trombofilia/sangre , Trombofilia/inmunología , Trombosis/sangre , Trombosis/inmunología , Tratamiento Farmacológico de COVID-19RESUMEN
Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung histopathology often reveals fibrin-based blockages in the small blood vessels of patients who succumb to the disease. Antiphospholipid syndrome is an acquired and potentially life-threatening thrombophilia in which patients develop pathogenic autoantibodies targeting phospholipids and phospholipid-binding proteins (aPL antibodies). Case series have recently detected aPL antibodies in patients with COVID-19. Here, we measured eight types of aPL antibodies in serum samples from 172 patients hospitalized with COVID-19. These aPL antibodies included anticardiolipin IgG, IgM, and IgA; anti-ß2 glycoprotein I IgG, IgM, and IgA; and anti-phosphatidylserine/prothrombin (aPS/PT) IgG and IgM. We detected aPS/PT IgG in 24% of serum samples, anticardiolipin IgM in 23% of samples, and aPS/PT IgM in 18% of samples. Antiphospholipid autoantibodies were present in 52% of serum samples using the manufacturer's threshold and in 30% using a more stringent cutoff (≥40 ELISA-specific units). Higher titers of aPL antibodies were associated with neutrophil hyperactivity, including the release of neutrophil extracellular traps (NETs), higher platelet counts, more severe respiratory disease, and lower clinical estimated glomerular filtration rate. Similar to IgG from patients with antiphospholipid syndrome, IgG fractions isolated from patients with COVID-19 promoted NET release from neutrophils isolated from healthy individuals. Furthermore, injection of IgG purified from COVID-19 patient serum into mice accelerated venous thrombosis in two mouse models. These findings suggest that half of patients hospitalized with COVID-19 become at least transiently positive for aPL antibodies and that these autoantibodies are potentially pathogenic.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , COVID-19/inmunología , Trombosis de la Vena/etiología , Adulto , Anciano , Anciano de 80 o más Años , Animales , Anticuerpos Antifosfolípidos/administración & dosificación , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/etiología , Síndrome Antifosfolípido/inmunología , COVID-19/sangre , COVID-19/complicaciones , Estudios de Cohortes , Estudios Transversales , Modelos Animales de Enfermedad , Trampas Extracelulares/metabolismo , Femenino , Humanos , Inmunoglobulina G/administración & dosificación , Inmunoglobulina G/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Neutrófilos/inmunología , Neutrófilos/metabolismo , Trombofilia/sangre , Trombofilia/etiología , Trombofilia/inmunología , Investigación Biomédica Traslacional , Trombosis de la Vena/sangre , Trombosis de la Vena/inmunologíaRESUMEN
Infection from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), though mainly a respiratory disease, can impair many systems, including causing hematological complications. Lymphopenia and hypercoagulability have been reported in adults with coronavirus disease 2019 (COVID-19) and are considered markers of poor prognosis. This review summarizes the hematological findings in children with SARS-CoV-2 infection. The majority of infected children had a normal leukocyte count, while the most common white blood cell abnormality was leukopenia. Lymphopenia, which may be a marker of severe disease, was rarer in children than in adults, possibly due to their immature immune system or due to the less severe manifestation of COVID-19 in this age group. Age may have an impact, and in neonates and infants the most common abnormality was lymphocytosis. Abnormalities of red blood cells and platelets were uncommon. Anemia and hypercoagulability were reported mainly in children presenting the novel multisystem inflammatory syndrome (MIS) associated with SARS-CoV-2.
Asunto(s)
Anemia/sangre , Betacoronavirus/metabolismo , Infecciones por Coronavirus/sangre , Linfopenia/sangre , Pandemias , Neumonía Viral/sangre , Trombofilia/sangre , Adolescente , Anemia/epidemiología , Anemia/inmunología , Betacoronavirus/inmunología , Biomarcadores/sangre , Plaquetas/inmunología , Plaquetas/metabolismo , COVID-19 , Niño , Preescolar , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Eritrocitos/inmunología , Eritrocitos/metabolismo , Femenino , Humanos , Lactante , Recién Nacido , Recuento de Leucocitos , Linfopenia/epidemiología , Linfopenia/inmunología , Masculino , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , SARS-CoV-2 , Trombofilia/epidemiología , Trombofilia/inmunologíaRESUMEN
Viscoelastic tests (VETs) have been used routinely for liver transplantation, cardiac surgery, and trauma, but only recently have found clinical utility in benign hematologic disorders. Therefore, guidelines for diagnosis and treatment of these disorders based on viscoelastic variables have been adapted from the existing transplant, cardiothoracic surgery, and trauma resuscitation literature. As a result, diagnostic and therapeutic strategies for benign hematologic disorders utilizing VETs are not uniform. Accordingly, even though there has been a recent increase in the utilization of VET for the diagnosis and treatment of such disorders, the literature is still in its early stages. Analysis of point-of-care viscoelastic tracings from benign hematologic disorders has the potential to allow prompt recognition of disease and to guide patient-specific intervention. Here we present a review describing the application of VETs to benign hematologic disorders.
Asunto(s)
Enfermedades Hematológicas/sangre , Pruebas en el Punto de Atención , Tromboelastografía , Animales , Enfermedades Autoinmunes/sangre , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/genética , Transfusión de Componentes Sanguíneos , Modelos Animales de Enfermedad , Predicción , Hemostasis/fisiología , Humanos , Tromboelastografía/instrumentación , Tromboelastografía/métodos , Trombofilia/sangre , Trombofilia/etiología , Trombofilia/genética , Trombofilia/inmunología , Vasculitis/sangreAsunto(s)
Betacoronavirus/patogenicidad , Coagulación Sanguínea , Activación de Complemento , Infecciones por Coronavirus/virología , Trampas Extracelulares/virología , Neutrófilos/virología , Neumonía Viral/virología , Trombofilia/virología , Trombosis/virología , Anciano , Anciano de 80 o más Años , Betacoronavirus/inmunología , COVID-19 , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/inmunología , Trampas Extracelulares/inmunología , Femenino , Interacciones Huésped-Patógeno , Humanos , Masculino , Persona de Mediana Edad , Neutrófilos/inmunología , Pandemias , Neumonía Viral/sangre , Neumonía Viral/inmunología , SARS-CoV-2 , Trombofilia/sangre , Trombofilia/inmunología , Trombosis/sangre , Trombosis/inmunologíaAsunto(s)
Betacoronavirus , Infecciones por Coronavirus/sangre , Pandemias , Neumonía Viral/sangre , Trombofilia/etiología , Pruebas de Coagulación Sanguínea , COVID-19 , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/inmunología , Síndrome de Liberación de Citoquinas/etiología , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/fisiopatología , Pruebas Diagnósticas de Rutina , Endotelio Vascular/inmunología , Endotelio Vascular/fisiopatología , Humanos , Neumonía Viral/complicaciones , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/inmunología , Síndrome de Dificultad Respiratoria/etiología , SARS-CoV-2 , Trombofilia/inmunología , Trombofilia/prevención & control , Trombosis/etiología , Trombosis/prevención & control , Tratamiento Farmacológico de COVID-19RESUMEN
The COVID-19 pandemic has caused monumental mortality, and there are still no adequate therapies. Most severely ill COVID-19 patients manifest a hyperactivated immune response, instigated by interleukin 6 (IL6) that triggers a so called "cytokine storm" and coagulopathy. Hypoxia is also associated with COVID-19. So far overlooked is the fact that both IL6 and hypoxia depress the abundance of a key anticoagulant, Protein S. We speculate that the IL6-driven cytokine explosion plus hypoxemia causes a severe drop in Protein S level that exacerbates the thrombotic risk in COVID-19 patients. Here we highlight a mechanism by which the IL6-hypoxia curse causes a deadly hypercoagulable state in COVID-19 patients, and we suggest a path to therapy.
Asunto(s)
Infecciones por Coronavirus , Síndrome de Liberación de Citoquinas , Hipoxia , Pandemias , Neumonía Viral , Proteína S , Trombofilia/inmunología , Enzima Convertidora de Angiotensina 2 , Anticoagulantes/metabolismo , Anticoagulantes/farmacología , Betacoronavirus/fisiología , COVID-19 , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/terapia , Síndrome de Liberación de Citoquinas/sangre , Síndrome de Liberación de Citoquinas/virología , Manejo de la Enfermedad , Humanos , Hipoxia/sangre , Hipoxia/etiología , Hipoxia/inmunología , Interleucina-6/sangre , Peptidil-Dipeptidasa A/metabolismo , Neumonía Viral/sangre , Neumonía Viral/inmunología , Neumonía Viral/terapia , Proteína S/metabolismo , Proteína S/farmacología , SARS-CoV-2 , Índice de Severidad de la EnfermedadRESUMEN
Thrombotic complications are frequent in COVID-19 and contribute significantly to mortality and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be upregulated in COVID-19. These include immune-mediated thrombotic mechanisms, complement activation, macrophage activation syndrome, antiphospholipid antibody syndrome, hyperferritinemia, and renin-angiotensin system dysregulation. We highlight biomarkers within each pathway with potential prognostic value in COVID-19. Lastly, recent observational studies have evaluated a role for the expanded use of therapeutic anticoagulation in COVID-19. We review strengths and weaknesses of these studies, and we also discuss the hypothetical benefit and anticipated challenges of fibrinolytic therapy in COVID-19.
Asunto(s)
COVID-19/complicaciones , SARS-CoV-2 , Trombosis/epidemiología , Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido , COVID-19/inmunología , COVID-19/terapia , Activación de Complemento , Enfermedad Crítica/epidemiología , Síndrome de Liberación de Citoquinas/epidemiología , Coagulación Intravascular Diseminada , Ferritinas/sangre , Humanos , Hiperferritinemia/epidemiología , Activación de Macrófagos , Embolia Pulmonar/epidemiología , Sistema Renina-Angiotensina/fisiología , Trombofilia/sangre , Trombofilia/epidemiología , Trombofilia/inmunología , Trombosis/sangre , Trombosis/inmunología , Tratamiento Farmacológico de COVID-19RESUMEN
Since the onset of the global pandemic in early 2020, coronavirus disease 2019 (COVID-19) has posed a multitude of challenges to health care systems worldwide. In order to combat these challenges and devise appropriate therapeutic strategies, it becomes of paramount importance to elucidate the pathophysiology of this illness. Coronavirus disease 2019, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is characterized by a dysregulated immune system and hypercoagulability. COVID-associated coagulopathy (CAC) was recognized based on profound d-dimer elevations and evidence of microthrombi and macrothrombi, both in venous and arterial systems. The underlying mechanisms associated with CAC have been suggested, but not clearly defined. The model of immunothrombosis illustrates the elaborate crosstalk between the innate immune system and coagulation. The rendering of a procoagulant state in COVID-19 involves the interplay of many innate immune pathways. The SARS-CoV2 virus can directly infect immune and endothelial cells, leading to endothelial injury and dysregulation of the immune system. Activated leukocytes potentiate a procoagulant state via release of intravascular tissue factor, platelet activation, NETosis, and inhibition of anticoagulant mechanisms. Additional pathways of specific relevance in CAC include cytokine release and complement activation. All these mechanisms have recently been reported in COVID-19. Immunothrombosis provides a comprehensive perspective of the several synergistic pathways pertinent to the pathogenesis of CAC.
Asunto(s)
Betacoronavirus , Trastornos de la Coagulación Sanguínea/virología , Infecciones por Coronavirus/complicaciones , Neumonía Viral/complicaciones , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/patología , COVID-19 , Infecciones por Coronavirus/fisiopatología , Infecciones por Coronavirus/virología , Células Endoteliales/patología , Células Endoteliales/virología , Humanos , Inmunidad Innata , Leucocitos/metabolismo , Leucocitos/patología , Pandemias , Neumonía Viral/fisiopatología , Neumonía Viral/virología , SARS-CoV-2 , Trombofilia/inmunología , Trombofilia/virología , Trombosis/etiología , Trombosis/inmunología , Trombosis/virologíaRESUMEN
In this paper, a model is proposed of the pathophysiological processes of COVID-19 starting from the infection of human type II alveolar epithelial cells (pneumocytes) by SARS-CoV-2 and culminating in the development of ARDS. The innate immune response to infection of type II alveolar epithelial cells leads both to their death by apoptosis and pyroptosis and to alveolar macrophage activation. Activated macrophages secrete proinflammatory cytokines and chemokines and tend to polarise into the inflammatory M1 phenotype. These changes are associated with activation of vascular endothelial cells and thence the recruitment of highly toxic neutrophils and inflammatory activated platelets into the alveolar space. Activated vascular endothelial cells become a source of proinflammatory cytokines and reactive oxygen species (ROS) and contribute to the development of coagulopathy, systemic sepsis, a cytokine storm and ARDS. Pulmonary activated platelets are also an important source of proinflammatory cytokines and ROS, as well as exacerbating pulmonary neutrophil-mediated inflammatory responses and contributing to systemic sepsis by binding to neutrophils to form platelet-neutrophil complexes (PNCs). PNC formation increases neutrophil recruitment, activation priming and extraversion of these immune cells into inflamed pulmonary tissue, thereby contributing to ARDS. Sequestered PNCs cause the development of a procoagulant and proinflammatory environment. The contribution to ARDS of increased extracellular histone levels, circulating mitochondrial DNA, the chromatin protein HMGB1, decreased neutrophil apoptosis, impaired macrophage efferocytosis, the cytokine storm, the toll-like receptor radical cycle, pyroptosis, necroinflammation, lymphopenia and a high Th17 to regulatory T lymphocyte ratio are detailed.